Floatz logo

Ktx-2001

mCRPC

K36 Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

513 Active assets in the mCRPC cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

Ktx-2001 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
metastatic prostate carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →